This discrepancy in outcomes following adjuvant chemotherapy has also been observed in other mucin-containing pancreatic tumors, like invasive IPMN, showing no survival benefit of adjuvant chemotherapy in early tumor stages [23–26]. Here, MUC5AC is linked to pancreatic intraductal papillary-mucinous neoplasm.